Two Drugs Offer Hope Against a Tough-to-Treat Prostate Cancer

THURSDAY, Feb. 8, 2018 (HealthDay News) — Two cancer drugs can stall the progression of a particularly hard-to-treat form of prostate cancer, a pair of new trials shows. Both a newly developed drug called apalutamide and an already approved drug called enzalutamide (Xtandi) kept prostate cancer from spreading for two years in men whose disease had not yet traveled to other parts of their bodies. Men newly diagnosed with prostate cancer that hasn’t spread are first treated with androgen-deprivation therapy — a medication that robs the tumor of the testosterone…

Read More